Funding profile · Orthodontic software and manufacturing
ArchForm
One Form D, filed in April 2020 for $7,842,080 fully sold to 15 investors, and nothing under Regulation D since. The capital record is short, closed and free of named funds.
$7.84MOffered and sold, the only Form D on record
15Investors in that offering, about $523,000 each
$0Left unsold when the notice was filed
2,360Days since the last Regulation D filing
Data as of September 22, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Winter 2018 | Y Combinator batch | Not disclosed | Y Combinator | YC data |
| Feb 24, 2020 | Equity offering, Rule 506(b), first sale | $7,842,080 offered | 15, none named | Form D |
| Apr 6, 2020 | Form D filed, offering closed | $7,842,080 sold, $0 remaining | Same 15 | Form D |
| Oct 2020 | Aligner factory opened in California | Not disclosed | Not disclosed | Trade press |
| 2020 to 2026 | Any later round | Nothing on file | Nothing on file | Not found |
What the filings show
ArchForm Inc. · Form D · filed Apr 6, 2020
- First sale
- Feb 24, 2020
- Offered
- $7,842,080 equity
- Sold
- $7,842,080 · $0 remaining
- Investors
- 15 · average about $522,805
- Minimum investment
- $0 · no non-accredited investors
- Exemption
- Rule 506(b)
- Sales compensation
- None reported · finders fees $0 · $0 of proceeds to officers
- Issuer
- Delaware corporation, principal place of business San Mateo, CA
- Self-reported industry
- Other Technology · revenue range: decline to disclose
- Related persons
- Andrew Martz (executive officer, director), San Mateo CA; Michael Terrill (director), Oostburg WI
- Filing
- SEC EDGAR, CIK 0001807066, accession 0001807066-20-000001
Reading the filings
- The checks were large and few.$7,842,080 across 15 investors is about $522,805 each. That is fund-sized or large-angel-sized money, not a crowd. Fifteen is also small enough that a single lead could account for most of it.
- The number is the tell.Offered equals sold exactly, at an odd figure, with $0 remaining. Issuers filing mid-round post a target such as $8,000,000 and report a partial. A notice sized to the penny of what was already collected is a filing made after the round closed.
- It was filed late.First sale was February 24, 2020; the notice landed April 6, 42 days later, against the 15 days Rule 503 asks for. Late Form Ds are common and nothing in the record suggests a consequence, but it is another sign of cleanup rather than a starting gun.
- No fund appears anywhere on the form.Two related persons are listed: founder Andrew Martz as executive officer and director, and Michael Terrill of Oostburg, Wisconsin as a director. A priced round this size usually seats a partner from the lead fund. No institution is named here, and no round announcement has surfaced in the trade press to fill the gap.
- The issuer did not call itself a health care company.ArchForm selected Other Technology as its industry group and declined to disclose revenue. Twenty months later the same entity took a Class II clearance from FDA’s dental panel. Anyone screening EDGAR by health care code would have missed this round.
- Six and a half years of silence.2,360 days have passed with no further Regulation D notice. Three readings fit: no new outside capital, capital raised under Section 4(a)(2), which requires no notice, or revenue doing the work. List prices are $50 per patient and $17 per aligner, against a claim of more than 7 million aligners made.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Regulatory | 510(k) K213916, cleared Dec 16, 2021 by third party review. Class II, 21 CFR 872.5470, product code PNN. No clearance on record for a finished aligner, a resin or the direct print hardware. | Public record |
| Marketing versus record | The direct print page describes its hardware as “a validated part of the FDA approval”. The company holds a clearance, not an approval, and that clearance covers software. | Differs from the record |
| Pricing | $50 per patient to export, $17 per factory-made aligner, $220 per setup, $899 or $999 per patient bundled with setups and refinements. | Company-stated |
| Manufacturing | Factory opened October 2020 with SLA and DLP printers, robotic trimming, up to 1,200 models a day and 10 to 14 day shipping. | Trade press |
| Scale claim | More than 7 million aligners made and more than $300 million saved, the saving footnoted as an average price comparison against one unnamed competitor. | Company-stated |
| Market size per doctor | Average US clear aligner fee was $6,301 in 2025 across 87 starts per orthodontist. The incumbent’s charge to the doctor was reported at about $1,700. | Independent |
What to watch
- A Form D for any round after April 2020. None in six years.
- A 510(k) covering the direct print aligner system, its resin or its curing hardware.
- Whether the direct print page is corrected from approval to clearance.
- Any named institutional investor. None appears on the only filing.
The ArchForm story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordForm D, ArchForm Inc., CIK 0001807066, accession 0001807066-20-000001
- Public recordFDA 510(k) database entry and clearance letter, K213916
- Public recordFDA product classification, product code PNN, orthodontic software
- IndependentThis 3D-printing startup helps orthodontists straighten your teeth
- IndependentArchForm’s 3D printed aligner factory set to reduce orthodontist costs
- IndependentArchForm launches aligner production powered by DLP 3D printing
- IndependentSteady year, shifting landscape: findings from the 2025 orthodontic practice survey
- CompanyArchForm pricing, direct print and home pages
- CompanyArchForm company listing, Y Combinator Winter 2018
Compiled from SEC and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in ArchForm. This page is not an offer to sell or a recommendation to buy any security.
